Janux Therapeutics, Inc.
JANX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$16.66
KIRA · Stoqly’s AI analyst, in plain words
- Janux Therapeutics, Inc. had $10.0M of revenue in fiscal 2025, down 5.6% on the year before.
- Its operating margin was −1,576.7%, down 643.1 pts: of every 100 in sales, about −1,577 is left after running the business.
- Janux Therapeutics, Inc. lost $114M in fiscal 2025.
- Free cash flow was −$83.3M in fiscal 2025, −832.8% of revenue.
Market cap
$1.0B
P/E
—
Revenue
$10.0M
Net income
−$114M
Free cash flow
−$83.3M
Operating margin
−1,576.7%
Janux Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−5.6%
No. Sales fell 5.6% last year.
Does it make a profit?
−1,136.3%
No. It lost money last year.
Does profit turn into cash?
−832.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Janux Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Janux Therapeutics, Inc.
- CIK
- 0001817713
Janux Therapeutics, Inc. · JANX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.6M | $8.6M | $8.1M | $10.6M | $10.0M |
| Revenue growth | — | 136.8% | −6.1% | 31.0% | −5.6% |
| Operating margin | −905.4% | −779.0% | −902.9% | −933.6% | −1,576.7% |
| Net income | −$32.7M | −$63.1M | −$58.3M | −$69.0M | −$114M |
| Net margin | −898.3% | −732.2% | −721.2% | −651.6% | −1,136.3% |
| Diluted EPS | −$1.39 | −$1.52 | −$1.32 | −$1.28 | −$1.83 |
| Cash | |||||
| Cash from operations | −$17.0M | −$42.9M | −$50.6M | −$43.8M | −$82.2M |
| Capital expenditure | $1.5M | $6.4M | $1.9M | $0.4M | $1.0M |
| Free cash flow | −$18.5M | −$49.4M | −$52.4M | −$44.2M | −$83.3M |
| FCF margin | −507.5% | −573.2% | −648.6% | −417.2% | −832.8% |
| Share count change | 2,471.3% | 76.2% | 6.1% | 22.1% | 15.3% |
| Debt and strength | |||||
| Cash and short-term investments | $375M | $327M | $344M | $1.0B | $967M |
| Shareholders' equity | $366M | $321M | $344M | $1.0B | $957M |
| Current ratio | 29.5x | 20.1x | 26.8x | 59.2x | 39.0x |
| Returns and quality | |||||
| Return on equity | −18.6% | −18.4% | −17.5% | −10.1% | −11.5% |
| Return on tangible equity | −8.9% | −19.7% | −16.9% | −6.7% | −11.9% |
| Piotroski F-score | 4 | 2 | 3 | 3 | 2 |
| Altman Z'' | 33.8 | 11.2 | 13.1 | 32.6 | 26.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.1M
7 insiders
Of sales under plans
67%
$0.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Janux Therapeutics, Inc. · JANX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $16.66 a share, the company is worth $1.0B.
Source: SEC EDGAR XBRL filings (CIK 0001817713). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.